The Week Ahead in Biotech (Dec. 6–Dec. 11)
The Omicron variant concerns were front and center in the markets in the week ended Dec. 3, and ...
Source: theepochtimes.com
Page 6 - Escalation Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Escalation Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Escalation Study Today - Breaking & Trending Today
IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Sarah Cannon Research Institute: Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO Annual Meeting
119 Abstracts and Presentations Featuring Sarah Cannon's Clinical Research and Care Insights Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society
Source: finanznachrichten.de
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
Share: Cohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction; anti-tumor activity observed in four of seven patients evaluated (including one unconfirmed partial response) Conference call and webcast with external guest presenters on Friday, June 4, 2021 at 4:30 P.M. ET ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity data from the ...
Source: benzinga.com
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
Share this article Share this article SOUTH SAN FRANCISCO, Calif., May 19, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced additional data from the Company's dose-escalation cohort of the Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) for patients with advanced, progressive ovarian cancer; the data will al...
Source: prnewswire.com